ArticleCancers2026
Dendritic Cell Served as Salvage Therapy for Advanced Hepatocellular Carcinoma Resistant to Tyrosine Kinase or Immune Checkpoint Inhibitors.
Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
BACKGROUND/
objectivesCurrent treatments for advanced hepatocellular carcinoma (HCC) are tyrosine kinase inhibitors (TKI) and immune checkpoint inhibitors (ICI). When HCC is resistant to TKI or ICI, subsequent available treatments are limited. Dendritic cells (DC) can activate antigen-specific cytotoxic T-cells and may be employed as a subsequent treatment when HCC is resistant to TKI or ICI treatments.
methodsFifty advanced HCC patients with resistance to ICI or TKI treatment were invited to have autologous DC therapy. DCs were propagated from peripheral blood monocytes and pulsed with tumor lysate. All the patients received ≥3 courses of DC intravenously. For the outcome analysis, 17 patients who were resistant to TKI or other traditional treatments were grouped into A, and 33 patients who were resistant to ICI treatment were grouped into B.
resultsFor group A patients, the median (interquartile) progression-free and overall survivals were 6 (3-16.3) and 19 (8-24) months, respectively. The 1-, 2- and 3-year overall survivals after DC therapy were 58.2%, 21.8%, and 14.6%, respectively. For group B patients, the median (interquartile) progression-free and overall survivals were 5.0 (4-8) and 9 (5-14.5) months, respectively. The 1-, 2- and 3-year overall survivals after DC therapy were 27.6%, 8.6% and 4.3%, respectively. Taking together 50 patients, the objective response rate was 6.0% and disease control rate was 72.0%. Only three patients (6.0%) had grade I-II hepatitis.
conclusionsDC therapy is a safe treatment for advanced HCC patients. DC can serve as a subsequent therapy to extend the patients' lives when TKI or ICI treatments are ineffective as advanced HCC treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.